Company News

Gmax Appoints Mr. Bing Zhu as CFO

-

Gmax, a clinical stage biopharmaceutical company focusing on G-protein coupled receptors (GPCRs) therapeutic antibody and Bibody development, today announced the appointment of Mr. Bing Zhu to the position of chief financial officer.

 

With an MBA from CEIBS, Mr. Zhu has more than 30 years of experiences in finance management, with 22 years in multi-national companies, fortune 500 companies and leading financial corporations. Mr. Zhu has successfully led several IPOs on NYSE, NASDAQ, TPEx, and has extensive expertise in fund raising, IPO, M&A, strategy, commercial operation and general management. Prior joining Gmax, Mr. Zhu served as the CFO and COO of Crown Bioscience International, and has led Crown Bioscience to be listed on TPEx in 2016.

 

About Gmax Biopharm

 

Gmax Biopharm LLC. is a clinical stage biopharmaceutical company focusing on G-protein coupled receptors (GPCRs) therapeutic antibody and Bibody development, to address the unmet medical needs in cardiovascular diseases, metabolic disorders and cancer. Gmax has established two proprietary world class antibody and Bibody discovery platforms targeting GPCRs, to develop first-in-class or best-in-class therapeutics. Leveraging these platforms, Gmax has propelled 2 antibodies in phase II/phase I clinical trials in Australia, with several antibodies/Bibodies in various stages of early discovery and preclinical testing for diabetes, obesity, PAH, NASH and heart failure.